Table of Contents
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels . Viradapt study, week 48 follow up and Pharmacological data.
Background
VIRADAPT: Trial Design
12 months Follow up Study
Patients and Methods
Patients and Methods: Statistical Analysis for the first 6 months randomized study
6 - 12 month follow-up study: Patients and Methods
Genotyping Technology
Mutations - Drug Resistance Table
Baseline Characteristics : Demographic data
Prior Antiretroviral Treatment
Baseline Characteristics-Frequency of Primary and Secondary RT mutations
Baseline Characteristics-Frequency of primary and secondary P mutations
Results
Mean changes in plasma HIV-RNA from baseline throughout 12 months in Control and Genotypic arms
Percentage of patients with plasma HIV-RNA below the limit of detection (200 copies/ml) in Control and Genotypic arms
Correlation of baseline primary protease mutations and randomization arm with changes in HIV RNA
Conclusions
Importance of Protease Inhibitor plasma levels in patients treated with Genotypic adapted therapy
Background
Background
Study Objective
Methods
Methods
Results
PI drug levels
Correlation HIV-RNA and plasma level
Pharmacokinetic data of P.I
Optimal Drug Concentrations
Results
Efficacy analysis based on drug levels and randomization arm
Efficacy analysis based on drug levels and randomization arm
Percentage of patients with plasma HIV-RNA below the limit of detection (200 copies/ml)
Predictive factors of virological response
Conclusions
Acknowledgements
|